Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hepatic Metabolic Flexibility in Obese With NAFL and NASH

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03678727
Recruitment Status : Not yet recruiting
First Posted : September 20, 2018
Last Update Posted : September 20, 2018
Sponsor:
Information provided by (Responsible Party):
University of Aarhus

Brief Summary:
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum from reversible hepatic steatosis to inflammation and fibrosis termed steatohepatitis (NASH) and cirrhosis. New evidence indicates that NAFLD is associated with development of heart failure, abnormal ventricular glucose and fatty acid (FA) utilisation and cardiosteatosis. The mechanisms behind cardiac involvement and the progression from NAFL to NASH are poorly understood but must include altered cardiac and intrahepatic lipid handling. In collaboration with renowned research groups from Oxford, Mayo Clinic and Copenhagen we plan comprehensive kinetic studies of heart and liver FA uptake and oxidation, ventricular function and substrate utilisation, and hepatic triglyceride (TG) secretion in order to assess mechanisms governing cardiac and hepatic lipid and glucose trafficking in subjects with NAFL and NASH and the relationship with heart function. In addition, we will assess skeletal muscle and adipose tissue enzyme activities, gene expression and protein concentrations in these subjects to define mechanisms involved in the cross-talk between heart, liver, muscle and adipose tissues. We will address these questions using innovative tracer techniques (11Cpalmitate, 11C acetate, 18FDG glucose PET tracers and TG tracers) in combination with hepatic vein catherisation to study cardiac and liver substrate trafficking, as well as NMR spectroscopy, echocardiography, muscle and fat biopsies in combination with state-of-the art muscle and adipose tissue enzyme kinetics, gene- and protein expression. Effects of acute exercise as well as GLP-1 agonist and SGLT-2 inhibitor treatment (alone and in combination) will be assessed. The overarching goals are to define abnormalities and differences between NAFLD and NASH in hepatic lipid (FA and TG) metabolism and to assess hepatic, adipose and skeletal muscle lipid and substrate utilisation.

Condition or disease
NAFLD - Nonalcoholic Fatty Liver Disease NASH - Nonalcoholic Steatohepatitis

Layout table for study information
Study Type : Observational
Estimated Enrollment : 16 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Hepatic and Cardiac Metabolic Flexibility in NAFL and NASH. Effects of Exercise, GLP-1 Agonist and SGL-T2 Inhibitor
Estimated Study Start Date : November 1, 2018
Estimated Primary Completion Date : November 1, 2020
Estimated Study Completion Date : May 1, 2021





Primary Outcome Measures :
  1. Hepatic metabolic flexibility in NAFL and NASH [ Time Frame: 2 years ]
    Systemic and Splanchnical FFA and VLDL-TG balance (uptake and release).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

8 obese subject men with NAFL (MR spectroskopi, fibro scanner) (BMI > 28). 8 obese subject men with NASH (MR spectroskopi, fibro scanner) (BMI > 28).

• age between 40-70 years Written consent before the start of the study

Criteria

Inclusion Criteria:

  • • 8 obese subject men with NAFL (MR spectroskopi, fibro scanner) (BMI > 28).

    • 8 obese subject men with NASH (MR spectroskopi, fibro scanner) (BMI > 28).
    • age between 40-70 years Written consent before the start of the study

Exclusion Criteria:

  • known current disease
  • Fixed medical drug consumption except antihypertensive drugs and statins. However, pause statins 3 weeks before the examination date
  • Blood donation within the last 3 months prior to the study
  • Participation in experiments involving radioactive isotopes within the last 6 months
  • Alcohol abuse (over 21 items per week for men and 14 for women)
  • Smoking
  • Weight over 130 kg
  • Cancer patients
  • Large intake of medication

Layout table for additonal information
Responsible Party: University of Aarhus
ClinicalTrials.gov Identifier: NCT03678727     History of Changes
Other Study ID Numbers: Jeyanproject2
First Posted: September 20, 2018    Key Record Dates
Last Update Posted: September 20, 2018
Last Verified: September 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases